Literature DB >> 23306586

Early acid-base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis.

Rinaldo Bellomo1, Miklos Lipcsey, Paolo Calzavacca, Michael Haase, Anjia Haase-Fielitz, Elisa Licari, Augustine Tee, Louise Cole, Alan Cass, Simon Finfer, Martin Gallagher, Joanne Lee, Serigne Lo, Colin McArthur, Shay McGuinness, John Myburgh, Carlos Scheinkestel.   

Abstract

PURPOSE: In acute kidney injury patients, metabolic acidosis is common. Its severity, duration, and associated changes in mean arterial pressure (MAP) and vasopressor therapy may be affected by the intensity of continuous renal replacement therapy (CRRT). We aimed to compare key aspects of acidosis and MAP and vasopressor therapy in patients treated with two different CRRT intensities.
METHODS: We studied a nested cohort of 115 patients from two tertiary intensive care units (ICUs) within a large multicenter randomized controlled trial treated with lower intensity (LI) or higher intensity (HI) CRRT.
RESULTS: Levels of metabolic acidosis at randomization were similar [base excess (BE) of -8 ± 8 vs. -8 ± 7 mEq/l; p = 0.76]. Speed of BE correction did not differ between the two groups. However, the HI group had a greater increase in MAP from baseline to 24 h (7 ± 3 vs. 0 ± 3 mmHg; p < 0.01) and a greater decrease in norepinephrine dose (from 12.5 to 3.5 vs. 5 to 2.5 μg/min; p < 0.05). The correlation (r) coefficients between absolute change in MAP and norepinephrine (NE) dose versus change in BE were 0.05 and -0.37, respectively.
CONCLUSIONS: Overall, LI and HI CRRT have similar acid-base effects in patients with acidosis. However, HI was associated with greater improvements in MAP and vasopressor requirements (clinical trial no. NCT00221013).

Entities:  

Mesh:

Year:  2013        PMID: 23306586     DOI: 10.1007/s00134-012-2800-0

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  35 in total

1.  The effect in humans of extracellular pH change on the relationship between serum potassium concentration and intracellular potassium.

Authors:  J M BURNELL; B H SCRIBNER; B T UYENO; M F VILLAMIL
Journal:  J Clin Invest       Date:  1956-09       Impact factor: 14.808

2.  Serum IL-6 and IL-1-ra with sequential organ failure assessment scores in septic patients receiving high-volume haemofiltration and continuous venovenous haemofiltration.

Authors:  Rohana Abdul Ghani; Soehardy Zainudin; Norella Ctkong; Ahmad Fauzi Abdul Rahman; Syed Rozaidi Wafa Syed Hussain Wafa; Marlyn Mohamad; Mohd Rizal Abdul Manaf; Rahimah Ismail
Journal:  Nephrology (Carlton)       Date:  2006-10       Impact factor: 2.506

3.  The impacts of continuous veno-venous hemofiltration on plasma cytokines and monocyte human leukocyte antigen-DR expression in septic patients.

Authors:  Zhang Peng; Peng Pai; Liu Hong-Bao; Li Rong; Wang Han-Min; Huang Chen
Journal:  Cytokine       Date:  2010-03-03       Impact factor: 3.861

4.  Continuous veno-venous hemofiltration improves hemodynamics in septic shock with acute renal failure without modifying TNFalpha and IL6 plasma concentrations.

Authors:  Kada Klouche; Pierre Cavadore; Pierre Portales; Jacques Clot; Bernard Canaud; Jean Jacques Béraud
Journal:  J Nephrol       Date:  2002 Mar-Apr       Impact factor: 3.902

5.  Impact of continuous veno-venous hemofiltration on acid-base balance.

Authors:  J Rocktäschel; H Morimatsu; S Uchino; C Ronco; R Bellomo
Journal:  Int J Artif Organs       Date:  2003-01       Impact factor: 1.595

6.  Modern quantitative acid-base chemistry.

Authors:  P A Stewart
Journal:  Can J Physiol Pharmacol       Date:  1983-12       Impact factor: 2.273

7.  Bicarbonate-based haemofiltration in the management of acute renal failure with lactic acidosis.

Authors:  P J Hilton; J Taylor; L G Forni; D F Treacher
Journal:  QJM       Date:  1998-04

Review 8.  Clinical review: anticoagulation for continuous renal replacement therapy--heparin or citrate?

Authors:  Heleen M Oudemans-van Straaten; John A Kellum; Rinaldo Bellomo
Journal:  Crit Care       Date:  2011-01-24       Impact factor: 9.097

Review 9.  Clinical review: the meaning of acid-base abnormalities in the intensive care unit part I - epidemiology.

Authors:  Kyle J Gunnerson
Journal:  Crit Care       Date:  2005-08-10       Impact factor: 9.097

10.  Delivered dose of renal replacement therapy and mortality in critically ill patients with acute kidney injury.

Authors:  Sergio Vesconi; Dinna N Cruz; Roberto Fumagalli; Detlef Kindgen-Milles; Gianpaola Monti; Anibal Marinho; Filippo Mariano; Marco Formica; Mariano Marchesi; Robert René; Sergio Livigni; Claudio Ronco
Journal:  Crit Care       Date:  2009-04-15       Impact factor: 9.097

View more
  13 in total

1.  How to explain and exploit the beneficial effects of high-volume hemofiltration on hemodynamics and strong ion gap.

Authors:  H M Oudemans-van Straaten; P W Elbers
Journal:  Intensive Care Med       Date:  2013-01-30       Impact factor: 17.440

2.  High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial.

Authors:  Olivier Joannes-Boyau; Patrick M Honoré; Paul Perez; Sean M Bagshaw; Hubert Grand; Jean-Luc Canivet; Antoine Dewitte; Claire Flamens; Wilfried Pujol; Anne-Sophie Grandoulier; Catherine Fleureau; Rita Jacobs; Christophe Broux; Hervé Floch; Olivier Branchard; Stephane Franck; Hadrien Rozé; Vincent Collin; Willem Boer; Joachim Calderon; Bernard Gauche; Herbert D Spapen; Gérard Janvier; Alexandre Ouattara
Journal:  Intensive Care Med       Date:  2013-06-06       Impact factor: 17.440

Review 3.  Non-pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.

Authors:  Yasushi Tsujimoto; Sho Miki; Hiroki Shimada; Hiraku Tsujimoto; Hideto Yasuda; Yuki Kataoka; Tomoko Fujii
Journal:  Cochrane Database Syst Rev       Date:  2021-09-14

4.  Year in review in Intensive Care Medicine 2013: I. Acute kidney injury, ultrasound, hemodynamics, cardiac arrest, transfusion, neurocritical care, and nutrition.

Authors:  Giuseppe Citerio; Jan Bakker; Matteo Bassetti; Dominique Benoit; Maurizio Cecconi; J Randall Curtis; Glenn Hernandez; Margaret Herridge; Samir Jaber; Michael Joannidis; Laurent Papazian; Mark Peters; Pierre Singer; Martin Smith; Marcio Soares; Antoni Torres; Antoine Vieillard-Baron; Jean-François Timsit; Elie Azoulay
Journal:  Intensive Care Med       Date:  2013-12-13       Impact factor: 17.440

5.  Timing of renal replacement therapy initiation for acute kidney injury.

Authors:  Alicia Isabel I Fayad; Daniel G Buamscha; Agustín Ciapponi
Journal:  Cochrane Database Syst Rev       Date:  2018-12-18

6.  Effects of high volume haemodiafiltration on inflammatory response profile and microcirculation in patients with septic shock.

Authors:  Kadri Tamme; Liivi Maddison; Rein Kruusat; Hans-Erik Ehrlich; Mirjam Viirelaid; Hartmut Kern; Joel Starkopf
Journal:  Biomed Res Int       Date:  2015-04-29       Impact factor: 3.411

Review 7.  High-volume hemofiltration for septic acute kidney injury: a systematic review and meta-analysis.

Authors:  Edward Clark; Amber O Molnar; Olivier Joannes-Boyau; Patrick M Honoré; Lindsey Sikora; Sean M Bagshaw
Journal:  Crit Care       Date:  2014-01-08       Impact factor: 9.097

8.  Hemodynamic consequences of severe lactic acidosis in shock states: from bench to bedside.

Authors:  Antoine Kimmoun; Emmanuel Novy; Thomas Auchet; Nicolas Ducrocq; Bruno Levy
Journal:  Crit Care       Date:  2015-04-09       Impact factor: 9.097

9.  Therapeutic plasma exchange does not reduce vasopressor requirement in severe acute liver failure: a retrospective case series.

Authors:  Ubbo F Wiersema; Susan W Kim; David Roxby; Andrew Holt
Journal:  BMC Anesthesiol       Date:  2015-03-08       Impact factor: 2.217

Review 10.  Intensity of continuous renal replacement therapy for acute kidney injury.

Authors:  Alicia I Fayad; Daniel G Buamscha; Agustín Ciapponi
Journal:  Cochrane Database Syst Rev       Date:  2016-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.